Evolus, Inc. (NASDAQ:EOLS) CFO Sells $119,286.96 in Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 8,996 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the sale, the chief financial officer now directly owns 173,583 shares in the company, valued at approximately $2,301,710.58. This represents a 4.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sandra Beaver also recently made the following trade(s):

• On Monday, December 23rd, Sandra Beaver sold 1,586 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total value of $17,208.10.

Evolus Stock Down 1.7 %

NASDAQ:EOLS opened at $13.03 on Friday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a market cap of $828.54 million, a PE ratio of -14.32 and a beta of 1.28. Evolus, Inc. has a 52-week low of $9.25 and a 52-week high of $17.82. The stock has a 50-day simple moving average of $13.42 and a 200 day simple moving average of $13.88.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Barclays raised their price target on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, March 5th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EOLS. Tri Locum Partners LP bought a new position in shares of Evolus during the fourth quarter worth about $8,198,000. Gilder Gagnon Howe & Co. LLC grew its stake in Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock valued at $7,753,000 after purchasing an additional 520,859 shares in the last quarter. Caligan Partners LP grew its stake in Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after purchasing an additional 498,900 shares in the last quarter. Allostery Investments LP bought a new position in Evolus in the fourth quarter valued at approximately $4,760,000. Finally, Altium Capital Management LLC grew its stake in Evolus by 93.0% in the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company’s stock valued at $7,562,000 after purchasing an additional 330,000 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.